Clinical review report: Ranolazine (Corzyna) (KYE Pharmaceuticals Inc.) : indication: stable angina pectoris, adults

The objective of this report is to perform a systematic review of the beneficial and harmful effects of ranolazine 500 mg and 1,000 mg ER tablets as an add-on therapy for the treatment of stable angina pectoris in adults who are inadequately controlled or intolerant to first-line antianginal therapi...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health August 2021, 2021
Edition:Version: Final
Series:CADTH common drug review
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The objective of this report is to perform a systematic review of the beneficial and harmful effects of ranolazine 500 mg and 1,000 mg ER tablets as an add-on therapy for the treatment of stable angina pectoris in adults who are inadequately controlled or intolerant to first-line antianginal therapies
Physical Description:1 PDF file (74 pages) illustrations